Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Meeting ReportAnnual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), Stockholm, Sweden, June 26–27, 2012

Biomarkers: Project Update from the GRAPPA 2012 Annual Meeting

Oliver FitzGerald and Philip J. Mease
The Journal of Rheumatology August 2013, 40 (8) 1453-1454; DOI: https://doi.org/10.3899/jrheum.130462
Oliver FitzGerald
From the Department of Rheumatology, St. Vincent’s University Hospital and Conway Institute for Biomolecular Research, University College, Dublin, Ireland; and Seattle Rheumatology Associates, Department of Rheumatology Research, Swedish Medical Center, and Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: oliver.fitzgerald@ucd.ie
Philip J. Mease
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

For members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), an important goal has been the identification of soluble biomarkers in psoriatic arthritis that might predict the development of radiographic progression. Work over the past year has resulted in approval of a draft protocol, and an announcement is forthcoming of the outcome of an assessment process for centers that applied to manage the project. GRAPPA is now ready to commence formal negotiations with potential funding partners and intends to initiate this project in the near future.

Key Indexing Terms:
  • CASPAR
  • PsA BioDam
  • PSORIATIC ARTHRITIS
  • BIOMARKERS
  • RADIOGRAPHIC PROGRESSION

In 2010, members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), together with the Outcome Measures in Rheumatology Clinical Trials (OMERACT) biomarker committee, agreed to support a study designed to validate soluble biomarkers as predictors of structural damage in psoriatic arthritis (PsA). The PsA BioDam study primary objective is to determine the independent predictive validity of several soluble biomarkers for predicting structural damage in PsA patients with active disease who are about to commence or change dose of standard disease-modifying antirheumatic drugs (DMARD) or initiate antitumour necrosis factor-α (TNF-α) therapy. The study will include assessment of biomarkers considered high priority candidates (e.g., high sensitivity C-reactive protein, matrix metalloproteinase-3, C-terminal propeptides of type II procollagen, or cleavage neoepitope of type II collagen) as well as a discovery arm for new candidate biomarkers. The primary radiographic outcome is increased number of erosions. Patients included will meet the ClASsification criteria for Psoriatic ARthritis (CASPAR)1, will have been diagnosed for > 3 months and < 2 years (i.e., early disease), and will agree to participate for a minimum of 24 months following informed consent. Primary exclusion criteria are corticosteroid therapy within 4 weeks of enrollment, prior treatment with anti-TNF-α therapy or other biologic, and presence of spinal or entheseal disease as the only disease manifestation. Serum and urine samples will be collected under strict guidelines at 6 study intervals, and radiographs of hands and feet obtained yearly. The goal of the study is to enroll and longitudinally track 1000 patients; power calculations were developed by the study’s statistician, Richard Cook. As evidenced by previous research efforts (e.g., CASPAR and GRAPPA Composite Exercise studies)1,2, it is anticipated that these patients can be readily recruited from GRAPPA member investigative centers, representing a diverse global patient population.

At the 2012 annual meeting of GRAPPA, members were advised of the status of the PsA BioDam project. A draft protocol has been updated and approved by the study steering committee, and is now circulating to GRAPPA members and potential industry partners, who attended an information meeting immediately following the GRAPPA meeting. To date, a number of pharmaceutical companies have indicated interest and await elaboration regarding study management and budget before proceeding further.

Members also discussed a call for proposals from clinical research organizations and institutions to manage the PsA BioDam. The advantages and disadvantages of several models were considered, including management by a company external to an academic center [such as Canadian Research and Education (CaRE) Arthritis3, which manages a similar BioDam study in rheumatoid arthritis]; and another model in which the study is conducted by an academic center with experience in conducting similar multicenter studies. Management applications have now been received and assessed by senior GRAPPA members, all of whom were independent of the organizations that responded. The applications were judged according to agreed criteria (Table 1), and the outcome from this process will be announced early in 2013.

View this table:
  • View inline
  • View popup
Table 1.

Criteria for assessment of applications to manage the PsA BioDam project.

Further, more structured engagement with potential industry partners will commence in early 2013. The PsA BioDam steering committee preference is that more than one pharmaceutical partner will be involved in supporting this project. It is also expected that the funding stream will be provided over ≥ 3-year time period. It is hoped that negotiations can be concluded by the end of second quarter 2013 and that the study can begin as soon as possible. Other issues that still need careful consideration include intellectual property, liability insurance, study management/flow, and institutional overheads. The steering group certainly prefers that GRAPPA retains all study intellectual property and that any risks and costs to GRAPPA are minimized.

REFERENCES

  1. 1.↵
    1. Taylor W,
    2. Gladman D,
    3. Helliwell P,
    4. Marchesoni A,
    5. Mease P,
    6. Mielants H
    . Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Helliwell PS,
    2. Fitzgerald O,
    3. Fransen J,
    4. Gladman DD,
    5. Kreuger GG,
    6. Callis Duffin K,
    7. et al.
    The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986–91.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. CaRE Arthritis — Arthritis Research and Education in Canada
    . Edmonton, Alberta (Internet. Accessed May 9, 2013.) Available from: http://www.carearthritis.com
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 40, Issue 8
1 Aug 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Biomarkers: Project Update from the GRAPPA 2012 Annual Meeting
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Biomarkers: Project Update from the GRAPPA 2012 Annual Meeting
Oliver FitzGerald, Philip J. Mease
The Journal of Rheumatology Aug 2013, 40 (8) 1453-1454; DOI: 10.3899/jrheum.130462

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Biomarkers: Project Update from the GRAPPA 2012 Annual Meeting
Oliver FitzGerald, Philip J. Mease
The Journal of Rheumatology Aug 2013, 40 (8) 1453-1454; DOI: 10.3899/jrheum.130462
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Keywords

CASPAR
PsA BioDam
PSORIATIC ARTHRITIS
BIOMARKERS
RADIOGRAPHIC PROGRESSION

Related Articles

Cited By...

More in this TOC Section

  • Ultrasound Imaging Module: Report from the GRAPPA 2012 Annual Meeting
  • GRAPPA Educational Initiatives: A report from the GRAPPA 2012 Annual Meeting
Show more Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), Stockholm, Sweden, June 26–27, 2012

Similar Articles

Keywords

  • CASPAR
  • PSA BIODAM
  • psoriatic arthritis
  • biomarkers
  • RADIOGRAPHIC PROGRESSION

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire